

## **Supporting Information**

for Adv. Sci., DOI: 10.1002/advs.201900037

Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy


Meng Yu, Xiaohui Duan, Yujun Cai, Fang Zhang, Shuqi Jiang, Shisong Han, Jun Shen,\* and Xintao Shuai\*

Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2019.

## **Supporting Information**


## Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy

Meng Yu, Xiaohui Duan, Yujun Cai, Fang Zhang, Shuqi Jiang, Shisong Han, Jun Shen\*, and Xintao Shuai\*




**Figure S1.** (a) Hydrodynamic diameters of MnO<sub>2</sub>-embedded nanoparticles before (BM) and after (BMI) encapsulation of therapeutic drug IPI549. (b) BMI was stable in aqueous solution and serum-containing medium over 4 weeks. (c-e) TEM images of BI, BN, and DiR-labeled


BMI. Scale bar: 200 nm. (f) Average sizes of different nanoparticles (n = 3).




**Figure S2.** T2-map and T2WI (a), measurements for longitudinal relaxivities (r2) (b) of BMI at various conditions. The magnetic relaxation properties of MnCl<sub>2</sub> as a positive control were measured as well.




**Figure S3.** Western blotting showing expressions of HIF-1 $\alpha$  and PD-L1 in 4T1 cells after incubation for 24 h with different formulations (n = 3). \*\*\*P < 0.001.




**Figure S4.** Fluorescence spectra of DiR-labeled BMI nanoparticles (Ex = 764 nm and Em = 780 nm).




**Figure S5.** Representative *in vivo* fluorescence imaging of 4T1 tumor-bearing mice intravenously injected with free DiR (8 mg kg<sup>-1</sup>)and saline at different time points.




**Figure S6.** A comparison of the T1WI signal intensity of tumors after i.v. (a) and i.t. (b) administration of BMI and  $MnCl_2$  (n = 3).




**Figure S7.** T2-weighted MR imaging (a) and signal intensities (b) of liver after i.v. administration of BMI (5 mg Mn kg<sup>-1</sup>) and MnCl<sub>2</sub> at different time points on T1WI (n = 3).




**Figure S8.** Representative photographs of lung tissues during the treatment course. The white dotted line indicated the lung metastatic foci.




**Figure S9.** Changes of body weights of tumor-bearing mice receiving various treatments (n = 5).




**Figure S10.** H&E staining for heart, spleen, and lung tissues from mice receiving various treatments at 18 d of treatment. Scale bar:  $100 \, \mu m$ .



**Figure S11.** Immunofluorescence images of tumor slices from mice 24 h after i.v. injection of PBS. Tumor hypoxia was determined by anti-HIF-1 $\alpha$  antibody staining. CD31 was analyzed for endothelial cells of tumor neovasculature. Scale bar: 100  $\mu$ m.



**Figure S12.** Immunofluorescence analysis for M1 and M2 markers in tumor tissue of mice receiving various treatments at 18 d of treatment. Scale bar:  $100 \mu m$ .



**Figure S13.** Immunofluorescence analysis for expressions of CD8 (a) and CD4 (b) over Foxp3 at 18 d of treatment (also see Figure 7a only showing the merged images). Scale bar:  $100 \, \mu m$ .